Short-term and long-term effect of diaphragm biofeedback training in gastroesophageal reflux disease: an open-label, pilot, randomized trial

被引:20
作者
Sun, X. [1 ,2 ]
Shang, W. [3 ]
Wang, Z. [1 ,2 ]
Liu, X. [1 ,2 ]
Fang, X. [1 ,2 ]
Ke, M. [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Dept Gastroenterol, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100730, Peoples R China
[3] Guangdong Provincail Tradit Chinese Med Hosptial, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China
来源
DISEASES OF THE ESOPHAGUS | 2016年 / 29卷 / 07期
关键词
anti-reflux barrier; diaphragm biofeedback training; gastroesophageal reflux; manometry; therapy; LOWER ESOPHAGEAL SPHINCTER; QUALITY-OF-LIFE; GERD; THERAPY; MANOMETRY; FREQUENCY;
D O I
10.1111/dote.12390
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
This study investigated the effectiveness of diaphragm biofeedback training (DBT) for patients with gastroesophageal reflux disease (GERD). A total of 40 patients with GERD treated at the Peking Union Medical College Hospital between September 2004 and July 2006 were randomized to receive DBT and rabeprazole proton pump inhibitor (PPI) or rabeprazole alone. The DBT + rabeprazole group received DBT during the 8-week initial treatment; the rabeprazole group did not. During the 6-month follow up, all patients took acid suppression according to their reflux symptoms, and the patients in the DBT + rabeprazole group were required to continue DBT. The primary outcome (used for power analysis) was the amount of acid suppression used at 6 months. Secondary outcomes were reflux symptoms, health-related quality of life (HRQL), and esophageal motility differences after the 8-week treatment compared with baseline. Acid suppression usage significantly decreased in the DBT + rabeprazole group compared with the rabeprazole group at 6 months (P < 0.05). At 8 weeks, reflux symptoms and GERD-HRQL were significantly improved in both groups (P < 0.05), without difference between them. Crural diaphragm tension (CDT) and gastroesophageal junction pressure (GEJP) significantly increased in the DBT + rabeprazole group (P < 0.05), but without change in lower esophageal sphincter (LES) pressure. There was no significant change in CDT, GEJP, and LES pressure compared with baseline in the rabeprazole group. In conclusion, long-term DBT could reduce acid suppression usage by enhancing the anti-reflux barrier, providing a non-pharmacological maintenance therapy and reducing medical costs for patients with GERD.
引用
收藏
页码:829 / 836
页数:8
相关论文
共 29 条
  • [1] ROLE OF THE DIAPHRAGM IN THE GENESIS OF LOWER ESOPHAGEAL SPHINCTER PRESSURE IN THE CAT
    BOYLE, JT
    ALTSCHULER, SM
    NIXON, TE
    TUCHMAN, DN
    PACK, AI
    COHEN, S
    [J]. GASTROENTEROLOGY, 1985, 88 (03) : 723 - 730
  • [2] Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: A meta-analysis of long-term omeprazole trials
    Carlsson, R
    Galmiche, JP
    Dent, J
    Lundell, L
    Frison, L
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (03) : 473 - 482
  • [3] Epidemiology of gastrooesophageal reflux disease: A systematic review
    Dent, J
    El-Serag, HB
    Wallander, MA
    Johansson, S
    [J]. GUT, 2005, 54 (05) : 710 - 717
  • [4] Non-pharmacological intervention for gastro-oesophageal reflux disease in primary care
    Dibley, Lesley B.
    Norton, Christine
    Jones, Roger
    [J]. BRITISH JOURNAL OF GENERAL PRACTICE, 2010, 60 (581) : e459 - e465
  • [5] Ding Zhao-lu, 2013, Zhonghua Yi Xue Za Zhi, V93, P3215
  • [6] Positive Effect of Abdominal Breathing Exercise on Gastroesophageal Reflux Disease: A Randomized, Controlled Study
    Eherer, A. J.
    Netolitzky, F.
    Hoegenauer, C.
    Puschnig, G.
    Hinterleitner, T. A.
    Scheidl, S.
    Kraxner, W.
    Krejs, G. J.
    Hoffmann, Karl Martin
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (03) : 372 - 378
  • [7] Fass R, 2001, AM J GASTROENTEROL, V96, P303
  • [8] Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study
    Fass, R
    Murthy, U
    Hayden, CW
    Malagon, IB
    Pulliam, G
    Wendel, C
    Kovacs, TOG
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (12) : 1595 - 1603
  • [9] Usage of supplemental alternative medicine by community-based patients with gastroesophageal reflux disease (GERD)
    Hayden, CW
    Bernstein, CN
    Hall, RA
    Vakil, N
    Garewal, HS
    Fass, R
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (01) : 1 - 8
  • [10] Systematic review: frequency and reasons for consultation for gastro-oesophageal reflux disease and dyspepsia
    Hungin, A. P. S.
    Hill, C.
    Raghunath, A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (04) : 331 - 342